Dataset Information

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

ABSTRACT: CBP and EP300 are highly homologous, bromodomain-containing transcription coactivators involved in numerous cellular pathways relevant to oncology. As part of our effort to explore the potential therapeutic implications of selectively targeting bromodomains, we set out to identify a CBP/EP300 bromodomain inhibitor that was potent both in vitro and in cellular target engagement assays and was selective over the other members of the bromodomain family. Reported here is a series of cell-potent and selective probes of the CBP/EP300 bromodomains, derived from the fragment screening hit 4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one.

SUBMITTER: Taylor AM

PROVIDER: S-EPMC4867486 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Taylor Alexander M AM Côté Alexandre A Hewitt Michael C MC Pastor Richard R Leblanc Yves Y Nasveschuk Christopher G CG Romero F Anthony FA Crawford Terry D TD Cantone Nico N Jayaram Hariharan H Setser Jeremy J Murray Jeremy J Beresini Maureen H MH de Leon Boenig Gladys G Chen Zhongguo Z Conery Andrew R AR Cummings Richard T RT Dakin Leslie A LA Flynn E Megan EM Huang Oscar W OW Kaufman Susan S Keller Patricia J PJ Kiefer James R JR Lai Tommy T Li Yingjie Y Liao Jiangpeng J Liu Wenfeng W Lu Henry H Pardo Eneida E Tsui Vickie V Wang Jian J Wang Yongyun Y Xu Zhaowu Z Yan Fen F Yu Dong D Zawadzke Laura L Zhu Xiaoqin X Zhu Xiaoyu X Sims Robert J RJ Cochran Andrea G AG Bellon Steve S Audia James E JE Magnuson Steven S Albrecht Brian K BK

ACS medicinal chemistry letters 20160315 5

CBP and EP300 are highly homologous, bromodomain-containing transcription coactivators involved in numerous cellular pathways relevant to oncology. As part of our effort to explore the potential therapeutic implications of selectively targeting bromodomains, we set out to identify a CBP/EP300 bromodomain inhibitor that was potent both in vitro and in cellular target engagement assays and was selective over the other members of the bromodomain family. Reported here is a series of cell-potent and ...[more]

PMID: 27190605

Dataset Information

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Publications

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor.
| S-EPMC7294707 | biostudies-literature

Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
| S-EPMC6889168 | biostudies-literature

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
| S-EPMC4933219 | biostudies-literature

Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
| S-EPMC6504645 | biostudies-literature

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
| S-EPMC4553799 | biostudies-literature

Activity of EP300/CBP bromodomain inhibitor CCS1477 across diverse hematologic malignancies
2023-11-28 | GSE207357 | GEO

Discovery of a Potent and Selective Covalent p300/CBP Inhibitor.
| S-EPMC8155265 | biostudies-literature

Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening.
| S-EPMC9630929 | biostudies-literature

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
| S-EPMC4948672 | biostudies-literature

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
| S-EPMC7479962 | biostudies-literature